A Phase 2 interventional study of Budigalimab and Placebo for Budigalimab in Human Immuno-deficiency Virus (HIV) Disease, sponsored by AbbVie. Terminated at 80 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.
Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide.
In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8.
Drug: Placebo for Budigalimab · Drug: Placebo for ABBV-382
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8.
Drug: Budigalimab · Drug: Placebo for ABBV-382
Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.
Drug: Placebo for Budigalimab · Drug: ABBV-382
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8.
Drug: Budigalimab · Drug: ABBV-382
Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.
Drug: Budigalimab · Drug: ABBV-382
Participants will receive open-label budigalimab Dose B on Day 1 and Weeks 2, 4, and 6 (Note, no ABBV-382 or placebo will be administered).
Drug: Budigalimab
Intravenous (IV) Infusion
Also known as: ABBV-181
IV Infusion
IV Infusion
IV Infusion
Subcutaneous (SC) Injection
Also known as: ABBV-181
Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart
Percentage of participants who achieve viral control (viral load \< 1000 copies/mL) without ART restart at Week 24.
Time frame: Week 24
Number of Participants With Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately Week 112
Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART
The median peak log10 viral load (at rebound) before re-starting ART.
Time frame: Up to 112 weeks
Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption
The median time to first rebound to ≥ 1000 copies/mL during ART interruption.
Time frame: Up to 112 weeks
| Milestone | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono |
|---|---|---|---|---|---|---|
| Started | 20 | 20 | 20 | 42 | 40 | 21 |
| Received randomized study treatment | 20 | 20 | 19 | 42 | 40 | 21 |
| Received study treatment other than randomized | 0 | 0 | 1 | 0 | 0 | 0 |
| Completed study treatment | 7 | 11 | 11 | 16 | 16 | 15 |
| Completed | 0 | 1 | 1 | 1 | 2 | 0 |
| Not completed | 20 | 19 | 19 | 41 | 38 | 21 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 | 7 | 2 | 1 |
| Withdrew: Withdrawal by subject due to adverse events | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 16 | 17 | 18 | 34 | 36 | 20 |
| Withdrew: Not disclosed | 0 | 1 | 0 | 0 | 0 | 0 |
Percentage of participants who achieve viral control (viral load \< 1000 copies/mL) without ART restart at Week 24.
| percentage of participants | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono |
|---|---|---|---|---|---|---|
| Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart | 5.0 (0.26 to 21.61) | 10.0 (1.81 to 28.26) | 0 (0.00 to 13.91) | 23.8 (13.53 to 37.03) | 10.0 (3.49 to 21.44) | 4.8 (0.24 to 20.67) |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Participants | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 17 | 19 | 15 | 40 | 36 | 17 |
The median peak log10 viral load (at rebound) before re-starting ART.
| log10 (copies/mL) | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono |
|---|---|---|---|---|---|---|
| Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART | 5.35 (1.3 to 6.6) | 5.01 (2.3 to 7.3) | 5.44 (3.7 to 7.7) | 5.22 (1.0 to 6.8) | 5.35 (1.5 to 6.6) | 4.96 (3.7 to 7.3) |
The median time to first rebound to ≥ 1000 copies/mL during ART interruption.
| days | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono |
|---|---|---|---|---|---|---|
| Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption | 26 (23.0 to 30.0) | 30 (22.0 to 43.0) | 30 (23.0 to 37.0) | 24 (22.0 to 30.0) | 26 (23.0 to 30.0) | 30 (23.0 to 32.0) |
Collected over All-cause mortality and adverse event tables include AEs reported from the time of informed consent and treatment-emergent events reported from the time of study drug administration to the end of the study. The median time on follow-up was 469, 427.5, 421, 389.5, 442 days for participants receiving Placebo, Budigalimab IV Mono, ABBV-382 IV Mono, ABBV-1882 IV Low, ABBV-1882 IV High in Part 1, and 253 days for participants receiving Budigalimab SC Mono in Part 2, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/21 (0%) | 0/21 (0%) | 13/21 (61.9%) |
| Part 1: Budigalimab IV Mono | 0/20 (0%) | 5/20 (25%) | 18/20 (90%) |
| Part 1: ABBV-382 IV Mono | 0/19 (0%) | 1/19 (5.3%) | 15/19 (78.9%) |
| Part 1: ABBV-1882 IV Low | 0/42 (0%) | 8/42 (19%) | 35/42 (83.3%) |
| Part 1: ABBV-1882 IV High | 0/40 (0%) | 8/40 (20%) | 34/40 (85%) |
| Part 2: Budigalimab SC Mono | 0/21 (0%) | 0/21 (0%) | 12/21 (57.1%) |
| Event | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono |
|---|---|---|---|---|---|---|
| APPENDICITISInfections and infestations | 0/21 | 2/20 | 0/19 | 0/42 | 1/40 | 0/21 |
| PYELONEPHRITIS ACUTEInfections and infestations | 0/21 | 0/20 | 1/19 | 0/42 | 0/40 | 0/21 |
| HERNIA PAINGeneral disorders | 0/21 | 1/20 | 0/19 | 0/42 | 0/40 | 0/21 |
| CELLULITISInfections and infestations | 0/21 | 1/20 | 0/19 | 0/42 | 0/40 | 0/21 |
| GLIOBLASTOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/21 | 1/20 | 0/19 | 0/42 | 0/40 | 0/21 |
| RETROVIRAL REBOUND SYNDROMEInfections and infestations | 0/21 | 0/20 | 0/19 | 2/42 | 0/40 | 0/21 |
| MYOCARDIAL INFARCTIONCardiac disorders | 0/21 | 0/20 | 0/19 | 0/42 | 1/40 | 0/21 |
| OBSTRUCTIVE PANCREATITISGastrointestinal disorders | 0/21 | 0/20 | 0/19 | 0/42 | 1/40 | 0/21 |
| HYPERSENSITIVITYImmune system disorders | 0/21 | 0/20 | 0/19 | 0/42 | 1/40 | 0/21 |
| ABSCESSInfections and infestations | 0/21 | 0/20 | 0/19 | 0/42 | 1/40 | 0/21 |
| Event | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono |
|---|---|---|---|---|---|---|
| FATIGUEGeneral disorders | 5/21 | 5/20 | 4/19 | 9/42 | 8/40 | 3/21 |
| RETROVIRAL REBOUND SYNDROMEInfections and infestations | 1/21 | 3/20 | 3/19 | 3/42 | 4/40 | 5/21 |
| MYALGIAMusculoskeletal and connective tissue disorders | 2/21 | 1/20 | 4/19 | 1/42 | 3/40 | 1/21 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/21 | 4/20 | 1/19 | 6/42 | 3/40 | 2/21 |
| HEADACHENervous system disorders | 3/21 | 2/20 | 3/19 | 6/42 | 5/40 | 3/21 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/21 | 0/20 | 0/19 | 0/42 | 6/40 | 0/21 |
| DIARRHOEAGastrointestinal disorders | 3/21 | 2/20 | 0/19 | 5/42 | 6/40 | 1/21 |
| COVID-19Infections and infestations | 1/21 | 3/20 | 1/19 | 3/42 | 2/40 | 1/21 |
| NAUSEAGastrointestinal disorders | 2/21 | 0/20 | 1/19 | 6/42 | 2/40 | 2/21 |
| NASOPHARYNGITISInfections and infestations | 0/21 | 1/20 | 2/19 | 1/42 | 5/40 | 1/21 |
ITT Population
| Age, Continuous(years) | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono | Total |
|---|---|---|---|---|---|---|---|
| Mean | 49.1 ± 12.45 | 47.3 ± 13.44 | 44.0 ± 10.75 | 44.6 ± 13.58 | 49.3 ± 10.72 | 42.1 ± 11.92 | 46.2 ± 12.32 |
| Age, Customized(Participants) | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono | Total |
|---|---|---|---|---|---|---|---|
| < 40 years | 7 | 5 | 9 | 17 | 8 | 10 | 56 |
| 40 - 64 years | 11 | 14 | 10 | 22 | 28 | 11 | 96 |
| ≥ 65 years | 2 | 1 | 1 | 3 | 4 | 0 | 11 |
| Sex/Gender, Customized(Participants) | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono | Total |
|---|---|---|---|---|---|---|---|
| Gender Identity — Cisgender | 19 | 18 | 18 | 40 | 37 | 21 | 153 |
| Gender Identity — Transgender Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gender Identity — Transgender Female | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Gender Identity — Gender Fluid | 0 | 1 | 2 | 1 | 2 | 0 | 6 |
| Gender Identity — Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gender Identity — Missing | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 2 | 1 | 8 | 5 | 1 | 21 |
| Male | 16 | 18 | 19 | 34 | 35 | 20 | 142 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 9 | 12 | 11 | 5 | 53 |
| Not Hispanic or Latino | 13 | 11 | 11 | 30 | 29 | 16 | 110 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Placebo | Part 1: Budigalimab IV Mono | Part 1: ABBV-382 IV Mono | Part 1: ABBV-1882 IV Low | Part 1: ABBV-1882 IV High | Part 2: Budigalimab SC Mono | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Asian | 1 | 1 | 1 | 2 | 2 | 0 | 7 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 4 | 2 | 6 | 8 | 7 | 9 | 36 |
| White | 14 | 16 | 13 | 31 | 29 | 12 | 115 |
| More than one race | 0 | 0 | 0 | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Oct 2023 to primary completion in Sep 2025, 23 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budigalimab · Trosunilimab